Investment
Features
FeesSafety
Academy
More
Pluang+

Cathie Wood hints large investors may be starting to buy Bitcoin, sees price reaching $750,000.

Market News
19 Oct 2026
Tokenpost
View Source
Bullish
Cathie Wood hints large investors may be starting to buy Bitcoin, sees price reaching $750,000.

Cathie Wood, CEO of ARK Invest, suggested that large asset allocators might be gradually rebalancing their portfolios and possibly taking initial positions in Bitcoin. While she did not provide specific purchase data or the number of new buyers, Wood expressed a bullish outlook, estimating Bitcoin's potential price could reach around $750,000 per coin. This indicates growing institutional interest but lacks concrete details on actual buying activity.

Large allocators possibly taking first Bitcoin positions, here is Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: Among 50 major cryptocurrencies priced on Pluang, 23 rose and 25 fell today. Notable movers include ENJ (Enjin Coin) at Rp487 with a 1-day change of -3.05% and a typical hold time of 105 days, FIL (Filecoin) at Rp18,553 with a 1-day change of -2.87% and a typical hold time of 100 days, and ATOM (Cosmos) at Rp31,176 with a 1-day change of +2.78% and a typical hold time of 61 days. Pluang order activity shows ENJ at 95% Sell / 5% Buy, FIL at 39% Sell / 61% Buy, and ATOM at 23% Sell / 77% Buy.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
1 hour ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
1 hour ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
1 hour ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
1 hour ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App